Clinical trials located in

Aachen

Aachen city is located in Germany. Currently, 20 clinical trials are being conducted in this city.

Aachen, located in western Germany near the borders with Belgium and the Netherlands, is renowned for its rich history and architectural marvels. The city’s centerpiece, Aachen Cathedral, is a UNESCO World Heritage site, famous for being the oldest cathedral in northern Europe and for holding the throne of Charlemagne, one of Europe’s most significant historical figures. Aachen is also known for its thermal springs, which have been attracting visitors since Roman times. The city played a pivotal role in the Carolingian Renaissance, a period marked by a revival of art, culture, and learning under Charlemagne’s reign.

  • CT-EU-00116343

    Venetoclax for controlling residual disease in chronic myeloid leukemia

    The study focuses on patients with Chronic Myeloid Leukemia (CML). It tests the effectiveness of Venetoclax, a drug, to control minimal residual stem cell disease after long-term treatment with Tyrosine Kinase Inhibitors (TKIs). The main goal of the study is to see if Venetoclax can help achieve a sustained deep molecular remission when TKIs are stopped. Participants in the study will take Venetoclax daily for 12 months following their discontinuation of TKI therapy. The study’s findings might lead to new practices for treating CML patients in deep molecular remission who are willing to undergo additional treatment.

    • Venetoclax
  • Exploring ELVN-001 in a trial for chronic myeloid leukemia safety and efficacy

    The study being described is a Phase 1 clinical trial of a drug named ELVN-001, which is being tested for the treatment of chronic myeloid leukemia (CML). This trial aims to evaluate the safety and effectiveness of ELVN-001, particularly its ability to be tolerated by patients and its impact on the disease. The study is designed to first determine the most suitable dose of ELVN-001 and then observe its effects on patients who have either relapsed from or are intolerant to standard treatments. The trial will involve administering the drug and monitoring patients for any reactions or improvements in their condition.

    • ELVN-001
  • Study of KRT-232 Combined with Ruxolitinib for Myelofibrosis Patients

    This here clinical trial is looking at a new drug called KRT-232 that’s taken by mouth. The study aims to see if combining KRT-232 with the existing drug ruxolitinib can help folks with myelofibrosis who ain’t responding well enough to just taking ruxolitinib alone.

    The main goal in the first part of the study is to find the right dose of KRT-232 to use when combined with ruxolitinib. They’ll be looking closely at any side effects to make sure the dose is safe. In the second part, they’ll check if the combination of the two drugs can shrink the size of the spleen by at least 35% after 6 months of treatment.

    • KRT-232
    • Ruxolitinib
  • Study Comparing Asciminib and Nilotinib for Newly Diagnosed Chronic Myeloid Leukemia

    This study examines the effects and tolerance of two drugs, asciminib and nilotinib, for treating a specific type of leukemia called Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in its chronic phase. The participants are adults who have been newly diagnosed and have not received previous treatment for this condition. They will be randomly assigned to receive either asciminib or nilotinib. The study aims to see which drug is better tolerated and how effective they are. Throughout the study, participants will be monitored for any side effects and the progress of their treatment until they either experience significant side effects, the disease progresses, or they decide to stop the treatment. Follow-up checks will also be conducted after the treatment ends.

    • Asciminib
    • Nilotinib
  • Comparison of zibotentan/dapagliflozin with dapagliflozin alone in the treatment of chronic kidney disease with high proteinuria

    The study aims to understand how to better treat people with chronic kidney disease (CKD) and high proteinuria. This study is in its third phase and involves multiple centers where participants will be closely monitored. The main goal is to compare the effectiveness, safety, and how well participants tolerate a combination treatment of zibotentan/dapagliflozin versus dapagliflozin alone.

    During this study, participants will be randomly assigned to one of two groups. One group will receive the combination of zibotentan and dapagliflozin, while the other group will receive only dapagliflozin. Both treatments aim to slow down the decline in kidney function, which is a major concern for people with CKD and high proteinuria. The key measure of success for this study is the change in eGFR from baseline, which is a test used to check how well the kidneys are working, specifically by measuring the estimated glomerular filtration rate (eGFR). This will be assessed at the 24-month mark of the study.

    This research is crucial because it could lead to better treatment options for those suffering from CKD and high proteinuria, potentially improving their quality of life and health outcomes.

    • Zibotentan/Dapagliflozin
    • Dapagliflozin
  • Study on Ravulizumab’s effect on Immunoglobulin A Nephropathy

    The study is looking into the effectiveness of a medication called ravulizumab for adults who have a kidney condition known as Immunoglobulin A Nephropathy (IgAN). This condition can lead to kidney damage over time, and the study aims to find out if ravulizumab can help reduce the amount of protein lost in urine—a common problem in IgAN—and slow down the decrease in kidney function.

    In this study, about 450 participants who are at a high risk of their disease getting worse will be chosen. These participants must have been on stable treatment for their IgAN for at least three months before the study starts. They will then receive either ravulizumab or a placebo, which is a treatment with no active drug, through an IV infusion based on their weight. The main goal is to see if those who receive ravulizumab have a significant improvement in their condition compared to those who receive the placebo.

    The study will have two main checkpoints. The first one, at Week 34, will check how much protein is in the urine, and the second one, at Week 106, will assess how well the kidneys are filtering waste from the blood. Additionally, a smaller group of participants with more advanced kidney issues will receive ravulizumab to further explore its effects.

    After the study ends at Week 106, participants will have the option to continue receiving ravulizumab in a follow-up period to see how long-term treatment affects their condition. This study is a chance for people with IgAN to potentially slow down their disease progression and improve their quality of life.

    • placebo
    • Ravulizumab
  • Iptacopan as a new hope for the treatment of paroxysmal nocturnal hemoglobinuria

    In this phase 3 trial, iptacopan’s efficacy and safety are assessed in adults with Paroxysmal Nocturnal Hemoglobinuria (PNH) who switch from standard anti-C5 treatments to iptacopan. The study, involving multiple centers, consists of an initial 8-week screening and a subsequent 24-week treatment phase with iptacopan. The primary focus is to determine if iptacopan can effectively manage PNH while maintaining patient safety. Participants showing benefits from iptacopan after the treatment period have the opportunity to continue in a roll-over extension study, allowing further observation of iptacopan’s long-term impacts.

    • Iptacopan
  • New therapy trial for relapsed large B-cell lymphoma

    This study is testing the use of two different treatments for diffuse large B-cell lymphoma (DLBCL), a type of blood cancer. Group One receives a mix of drugs, including polatuzumab vedotin, rituximab, ifosfamide, carboplatin, and etoposide (collectively called Pola-R-ICE). Group Two receives a similar mix without polatuzumab vedotin, known as R-ICE. Patients will be randomly sorted into the two groups. The test treatment spans three months and includes three chemotherapy treatments. After that, doctors will follow up with patients for at least 21 months. The goal is to compare how well the two treatments work to control DLBCL. Different factors, like progress of the disease, the response to treatment, and overall health will be observed to determine how efficient these treatments are.

    • Mabthera
    • Ifosfamide
    • Polatuzumab vedotin
    • Etoposide
    • Carboplatin
  • Evaluating durvalumab in small cell lung cancer treatment

    This study examines the effectiveness and safety of adding durvalumab to standard radiochemotherapy for patients with limited-stage small cell lung cancer (SCLC). It’s an open-label trial where patients are randomly divided into two groups. One group receives durvalumab in combination with standard therapy, while the other receives only standard therapy. The primary goal is to assess how well the combination therapy works in preventing cancer progression, with a focus on patient survival and response to treatment.

    • Durvalumab
  • Study on solnatide’s effect on acute respiratory distress syndrome

    The study aims to assess a new medication, Solnatide, for individuals with a severe lung condition known as ARDS (Acute Respiratory Distress Syndrome), which results in fluid accumulation in the lungs. Participants will inhale varying amounts of Solnatide over a one-week period, and their response to the medication will be closely monitored. The primary objectives are to confirm the safety of the medicine and evaluate its potential benefits for these patients. Safety assessments will involve monitoring for side effects and adverse health events. Additionally, medical tests will be conducted to measure the level of fluid in the lungs and assess the impact of the drug on participants’ breathing. The results of this study will play a crucial role in determining the broader applicability of Solnatide in the future.

    • Solnatide
    • 0.9% Saline Solution
  • A clinical trial evaluating Tominersen in the treatment of early stages of Huntington’s disease

    This clinical trial is focused on evaluating the investigational drug, tominersen, in people in the early stages of Huntington’s disease, a genetic disorder characterized by the progressive loss of nerve cells in the brain.

    The aim of this study is to understand the potential of tominersen to slow the progression of the disease and improve quality of life by administering different doses of this drug or a placebo directly into the spinal cord to reach the areas of the brain most affected by the disease. Participants’ health will be closely monitored and a series of assessments will be conducted to track changes in motor function, cognitive abilities and emotional well-being. Additionally, the study will measure specific biomarkers to assess the biological impact of treatment, offering valuable information for tailoring future therapies. This study provides an important opportunity to better understand Huntington’s disease and explore effective treatment options.

    • Placebo
    • Tominersen
  • Study on new drug effects in treating blood disorder

    In this study, the drug being investigated is INCA033989. It will be given alone or in combination with ruxolitinib in people with a condition known as myeloproliferative neoplasms. The primary goal of the research is to assess safety, comfort, and the occurrence of possible harmful effects, especially at specific dosages. Additionally, doctors will try to determine the highest dose participants can tolerate without serious side effects. Importantly, observations will be made regarding any changes in the disease or participants’ subjective experiences.

    • INCA033989- new potential medication for myelofibrosis (MF) and essential thrombocythemia (ET)
    • Ruxolitinib
  • Examining ultrasound-assisted and standard treatment for lung clots

    In this study, researchers want to compare two treatments for a disease called pulmonary embolism. This is a disease in which a blood clot blocks the vessels that supply blood to the lungs. The group of people taking part in the study will be randomly assigned to receive either blood-thinning medications alone (anticoagulation) or blood-thinning medications using a blood clot-dissolving device. The name of this device is the EkoSonic endovascular device. The research will continue for 12 months, and the health of the participants will be regularly monitored.

    • Anticoagulation with heparin
  • Study testing Ruxolitinib cream for Prurigo Nodularis treatment

    This study is testing a cream with Ruxolitinib to see if it’s safe and effective for people with a skin condition called Prurigo Nodularis (PN). The study has three main parts. In the first 12 weeks, participants will receive either the cream with Ruxolitinib or placebo (also known as vehicle-controlled) treatment. After that, all participants will receive the cream with Ruxolitinib for another 40 weeks. After that, there will be an extra 30 days to keep an eye on safety. The trial will measure success by checking if the cream can reduce itchiness. Treatment success will be evaluated by medical professionals, considering factors such as the number of skin nodules and the extent of redness and crusting in the condition’s severity.

    • Ruxolitinib
  • Testing ustekinumab treatment for severe ulcerative colitis

    This clinical trial is focused on understanding the safety and effectiveness of a medication named Ustekinumab in children and adolescents who are experiencing moderate to severe Ulcerative Colitis (UC), a type of inflammatory bowel disease that causes long-lasting inflammation and ulcers in the digestive tract. The study administers Ustekinumab initially through an IV (intravenous infusion) and then as a subcutaneous injection. The main aims are to determine whether Ustekinumab can help these young patients achieve clinical remission, meaning their UC symptoms are reduced or completely go away, and to monitor how the drug behaves in their bodies. Throughout the trial, the health and safety of the participants are closely monitored.

    • Ustekinumab
  • Pemigatinib in the treatment of cholangiocarcinoma

    This study focuses on comparing the impact and safety of two treatments: Pemigatinib and a chemotherapeutic combination of Gemcitabine and Cisplatin. These treatments are being tested on people who have an advanced form of liver cancer, cholangiocarcinoma, which cannot be removed by surgery or has spread to other parts of the body, and is associated with a particular genetic change known as FGFR2 rearrangement. The aim is to examine the effectiveness of Pemigatinib in comparison to the chemotherapy combination of Gemcitabine and Cisplatin. Measurements of success will be based on how much the cancer shrinks, the duration of response to treatment, as well as any side effects encountered.

    • Pemigatinib
    • Gemcitabine
    • Cisplatin
  • Evaluating different drugs for advanced multiple myeloma

    This study is conducted to see how good a medication called Elranatamab is for individuals having multiple myeloma, a blood cancer that affects the marrow inside your bones. This study will use Elranatamab alone, or pair it with another medication called Daratumumab. The aim is to see if Elranatamab alone or mixed with Daratumumab is better than the current treatment of Daratumumab mixed with two other medications named Pomalidomide and Dexamethasone. This research is primarily for individuals who have undergone previous treatments with medications, Lenalidomide and a proteasome inhibitor. The study has two parts. The aim of the first part is the safety test and effects of Elranatamab mixed with Daratumumab at various doses. The second part will divide participants into three groups: Elranatamab alone, Elranatamab with Daratumumab, or the current treatment. The goal is to observe which treatment is safer and works better.

    • Elranatamab
    • Pomalidomide
    • Dexamethasone
    • Daratumumab
  • Monitoring the long-term safety of Nivolumab for cancer survivors

    This study is designed to understand the long-term effects of a medicine called Nivolumab in patients who have fought against various forms of cancer. In this study, the focus is on closely examining the long-term efficiency and safety of Nivolumab. Participants in the investigation encompass both current and past users of Nivolumab.

    • Nivolumab
  • Testing Milvexian’s effectiveness in preventing repeat strokes

    This research trial, called LIBREXIA-STROKE, will test a medication called Milvexian on those who have recently had a stroke or a high-risk ‘mini-stroke’. In its 3rd testing phase, the study will involve a system where the patients won’t know whether they are receiving the actual drug or a substitute with no effect, referred to as a ‘placebo’, to maintain fairness. Milvexian is a medication that can potentially reduce the risk of having another stroke, and this trial aims to observe how effective it is in doing so. The trial will look at when the first stroke happens after starting the trial, if other major heart or limb diseases occur, or if strokes occur in the first 90 days.

    • Milvexian
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab

See more clinical trials in other cities in Germany:

.